Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorsPIERO D. DALERBA, SARA VIRAGOVA
Estimating the term…
The method of treating adenoid cystic carcinoma or other cancer tumors includes the administration of an effective dosage of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling to a patient in need thereof, alone or in combination with other cancer treatment. Non-limiting examples of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling include 4-[(1E)-2-[5,6-Dihydro-5,5-dimethyl-8-(2-phenylethynyl)-2-naphthalenyl]ethenyl]benzoic acid (commonly referred to as “BMS493”) and 4-[2-[5,6-Dihydro-5,5-dimethyl-8-(4-methylphenyl)-2-naphthalenyl] ethynyl]benzoic acid (commonly referred to as “AGN193109”). Alternatively, prior to administration of the inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling, a direct agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling may be administered to the patient. Non-limiting examples of a direct agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling include all-trans retinoic acid (ATRA), isotretinoin, alitretinoin, and bexarotene.
A method of treating adenoid cystic carcinoma, comprising the step of administering an effective dosage of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling to a patient in need thereof.
A method of treating adenoid cystic carcinoma, comprising the steps of:
A method of anti-tumor treatment comprising the step of administering an effective dosage of an inverse agonist of retinoic acid receptor (RAR) or retinoid x receptor (RXR) signaling to a patient in need thereof, wherein the tumor is associated with one or more of the following types of cancer:
Dependencies are inferred from the claim text.